GlassScriptPhysician profile
Nora W Perkins
NPI 1760641096
$299,935.07
in general payments reported to CMS, 2019-2025
30 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $21K · 2021: $42K · 2022: $44K · 2023: $27K · 2024: $39K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $90K · Travel and Lodging: $7,518 · Food and Beverage: $6,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $90,230.25 |
| Travel and Lodging | $7,518.06 |
| Food and Beverage | $6,584.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $239,702.84 | 2019-2025 | Scopis Ent, Latera, Xpress Loprofile |
| Aerin Medical INC. | $47,830.25 | 2023-2025 | |
| Genzyme Corporation | $9,509.36 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $343.43 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $247.56 | 2019-2025 | Nucala, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $225.47 | 2019-2025 | Xywav |
| Csl Behring | $200.35 | 2023-2025 | Hizentra, Andembry, Haegarda |
| Intersect Ent, INC. | $194.72 | 2020-2021 | |
| Acclarent, INC | $177.85 | 2019-2021 | |
| Neurent Medical Limited | $158.56 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Spirair, INC. | $132.89 | 2024 | Septalign |
| Harmony Biosciences LLC | $122.59 | 2022-2024 | Wakix |
| Biosense Webster, INC. | $121.82 | 2023 | Pentaray Nav |
| Astrazeneca Pharmaceuticals LP | $112.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $103.42 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $100.66 | 2022-2024 | Propel |
| Takeda Pharmaceuticals U.S.A., INC. | $95.20 | 2022-2023 | Cuvitru |
| Grifols USA, LLC | $91.76 | 2022-2023 | Xembify |
| Amgen INC. | $84.14 | 2025 | Tezspire |
| Optinose US, INC. | $77.53 | 2019-2024 | |
| Axsome Therapeutics, INC. | $62.05 | 2022-2025 | Sunosi |
| Alk-Abello, INC | $46.88 | 2019-2021 | |
| Pfizer INC. | $38.55 | 2019 | |
| Depuy Synthes Sales INC. | $36.20 | 2022 | |
| Ethicon US, LLC | $35.37 | 2019 | |
| Kaleo, INC. | $21.65 | 2023 | Auvi-Q |
| Kowa Pharmaceuticals America, INC. | $19.26 | 2023 | Seglentis |
| Karl Storz Endoscopy-America | $15.64 | 2019 | |
| Merck Sharp & Dohme LLC | $14.59 | 2023 | |
| Shire North American Group INC | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.